Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | ALB | P02768 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.53 |
| ▸ | ABL1 | P00519 | 4/20 | 0.50 |
| ▸ | RIN1 | Q13671 | 4/20 | 0.50 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29318369 | 0.88 | YTHDC1 (0.59) | ALDH1A1LMNAALBMAPK1ADORA3 | |
| SCHEMBL2041441 | 0.88 | YTHDC1 (0.59) | ALDH1A1LMNAALBMAPK1ADORA3 | |
| SCHEMBL9589274 | 0.88 | ALDH1A1 (0.54) | ALDH1A1LMNAALBMAPK1ADORA3 | |
| SCHEMBL9589282 | 0.88 | ALDH1A1 (0.54) | ALDH1A1LMNAALBMAPK1ADORA3 | |
| SCHEMBL9587631 | 0.88 | ALDH1A1 (0.54) | ALDH1A1LMNAALBMAPK1ADORA3 | |
| SCHEMBL20419240 | 0.86 | ALDH1A1 (0.57) | ALDH1A1LMNAALBMAPK1ABL1 | |
| SCHEMBL23982425 | 0.85 | ABL1 (0.66) | ABL1RIN1NR2F2 | |
| SCHEMBL23998782 | 0.85 | ABL1 (0.54) | ALDH1A1LMNAALBMAPK1ADORA3 | |
| SCHEMBL22524082 | 0.84 | ADORA3 (0.47) | ADORA3NR2F2 | |
| SCHEMBL13467417 | 0.84 | NR2F2 (0.57) | ADORA3ABL1RIN1NR2F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2509949-B1 | PYRIDINONE HYDROXYCYCLOPENTYL CARBOXAMIDES: HIV INTEGRASE INHIBITORS WITH THERAPEUTIC APPLICATIONS | UNIV GEORGIA (US) | 2014-04-23 | — | — | EP | claimed |
| US-8703801-B2 | Pyridinone hydroxycyclopentyl carboxamides: HIV integrase inhibitors with therapeutic applications | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2014-04-22 | — | — | US | claimed |
| US-20120282218-A1 | PYRIDINONE HYDROXYCYCLOPENTYL CARBOXAMIDES: HIV INTEGRASE INHIBITORS WITH THERAPEUTIC APPLICATIONS | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION INC. (US) | 2012-11-08 | — | — | US | claimed |
| EP-2509949-A2 | PYRIDINONE HYDROXYCYCLOPENTYL CARBOXAMIDES: HIV INTEGRASE INHIBITORS WITH THERAPEUTIC APPLICATIONS | University Of Georgia Research Foundation, Inc. (US) | 2012-10-17 | — | — | EP | claimed |
| WO-2011071849-A2 | PYRIDINONE HYDROXYCYCLOPENTYL CARBOXAMIDES: HIV INTEGRASE INHIBITORS WITH THERAPEUTIC APPLICATIONS | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2011-06-16 | — | — | WO | claimed |
| US-20100092427-A1 | Pyridinone Diketo Acids: Inhibitors of HIV Replication in Combination Therapy | THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION (US) | 2010-04-15 | — | — | US | claimed |
| EP-2046328-A2 | PYRIDINONE DIKETO ACIDS: INHIBITORS OF HIV REPLICATION IN COMBINATION THERAPY | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2009-04-15 | — | — | EP | claimed |
| WO-2008010953-A2 | PYRIDINONE DIKETO ACIDS: INHIBITORS OF HIV REPLICATION IN COMBINATION THERAPY | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2008-01-24 | — | — | WO | claimed |
| US-20070264241-A1 | Compounds for Enhanced Cancer Therapy | ZGENE A/S (DK) | 2007-11-15 | — | — | US | claimed |
| WO-2007106450-A2 | DIKETO ACIDS WITH NUCLEOBASE SCAFFOLDS: ANTI-HIV REPLICATION INHIBITORS TARGETED AT HIV INTEGRASE IN COMBINATION THERAPY | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2007-09-20 | — | — | WO | claimed |
| WO-2005079849-A2 | COMPOUNDS FOR ENHANCED CANCER THERAPY | ZGENE A/S (DK) | 2005-09-01 | — | — | WO | claimed |
| US-20050026902-A1 | Methods and compositions for the treatment or prevention of human immunodeficiency virus and related conditions using cyclooxygenase-2 selective inhibitors and antiviral agents | PHARMACIA CORPORATION | 2005-02-03 | — | — | US | claimed |
| US-9650360-B2 | Anti-mycobacterial drugs against tuberculosis | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2017-05-16 | — | — | US | disclosed |
| EP-2831056-B1 | NEW ANTI-MYCOBACTERIAL DRUGS AGAINST TUBERCULOSIS | THE UNIV OF GEORGIA RES FOUND INC (US) | 2016-12-14 | — | — | EP | disclosed |
| US-20150050237-A1 | NEW ANTI-MYCOBACTERIAL DRUGS AGAINST TUBERCULOSIS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-02-19 | — | — | US | disclosed |
| EP-2831056-A1 | NEW ANTI-MYCOBACTERIAL DRUGS AGAINST TUBERCULOSIS | The University Of Georgia Research Foundation, Inc (US) | 2015-02-04 | — | — | EP | disclosed |
| EP-1520015-A2 | PLANT DEOXYRIBONUCLEOSIDE KINASE ENZYMES AND THEIR USE | Knecht, Wolfgang (SE) | 2005-04-06 | — | — | EP | disclosed |
| US-20050026902-A1 | Methods and compositions for the treatment or prevention of human immunodeficiency virus and related conditions using cyclooxygenase-2 selective inhibitors and antiviral agents | PHARMACIA CORPORATION | 2005-02-03 | — | — | US | disclosed |
| WO-2005005626-A1 | YELLOW FEVER MOSQUITO DEOXYRIBONUCLEOSIDE KINASES AND ITS USE | ZGENE A/S (DK) | 2005-01-20 | — | — | WO | disclosed |
| WO-2004003185-A2 | PLANT DEOXYRIBONUCLEOSIDE KINASE ENZYMES AND THEIR USE | KNECHT WOLFGANG (SE) | 2004-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100092427-A1 | Pyridinone Diketo Acids: Inhibitors of HIV Replication in Combination Therapy | TKT, DHFR, DTYMK | ALDH1A1 1645/4885LMNA 3285/4885ALB 4476/4885 |
| US-20120282218-A1 | PYRIDINONE HYDROXYCYCLOPENTYL CARBOXAMIDES: HIV INTEGRASE INHIBITORS WITH THERAPEUTIC APPLICATIONS | PAICS, DUT, AADAC | ALDH1A1 2717/4885LMNA 3895/4885ALB 4691/4885 |
| US-20070264241-A1 | Compounds for Enhanced Cancer Therapy | TYMP, BAD, NUDT1 | ALDH1A1 1106/4885LMNA 1899/4885ALB 4112/4885 |
| US-20150050237-A1 | NEW ANTI-MYCOBACTERIAL DRUGS AGAINST TUBERCULOSIS | FNTB, ABCC1, TBCD | ALDH1A1 3146/4885LMNA 3477/4885ALB 3199/4885 |
| US-20050026902-A1 | Methods and compositions for the treatment or prevention of human immunodeficiency virus and related conditions using cyclooxygenase-2 selective inhibitors and antiviral agents | PTGS2, PTGS1, PTGES2 | ALDH1A1 1263/4885LMNA 3478/4885ALB 4205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.